No profile data available.
Supernus Pharmaceuticals, Inc. (SUPN) is a healthcare company in the brain and nerve treatment drugs industry, based in Rockville, United States, with about 778 full-time employees.
It reported revenue of $718.95 million for fiscal year 2025, up 8.6% from fiscal year 2024, and net income of -$38.55 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $219.06 million, up 32.4% from a year before. Its market capitalization was $2.48 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a biopharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States.
Supernus Pharmaceuticals reported $718.95 million in revenue for fiscal year 2025, up 8.6% from $661.82 million in fiscal year 2024. In Q2 2026 revenue was $219.06 million.
$2.48 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (brain and nerve treatment drugs) include Acadia Pharmaceuticals Inc. (ACAD), Denali Therapeutics Inc. (DNLI), Dyne Therapeutics, Inc. (DYN), Harmony Biosciences Holdings, Inc. (HRMY).